J Korean Ophthalmol Soc.  2008 Aug;49(8):1356-1359. 10.3341/jkos.2008.49.8.1356.

Malignant Hyperthermia in a Patient with Partially Accommodative Esotropia

• Kwon SW
• Kim KH
• Kim WY
• Kim SH

• KMID: 2211745
• DOI: http://doi.org/10.3341/jkos.2008.49.8.1356

Abstract

PURPOSE
Malignant hyperthermia is hypermetabolic disorder of skeletal muscle that manifests during general anesthesia. Strabismus and ptosis are important risk factors in ophthalmology field for malignant hyperthermia. We report a case of malignant hyperthermia in patient with partially accommodative esotropia.
CASE SUMMARY
A 6-year-old patient was supposed to undergo a surgical correction for 20 prism diopters of right esotropia after correction of hypermetropia. Because the patient showed tachycardia and hyperthermia just after inhalation of sevoflurane, we interrupted general anesthesia and cancelled the surgery. The patient was transferred to the intensive care unit. In this case, no significant familial and past histories were found. Intractable tachycardia and hyperthermia that had not responded to conservative management improved after two administration of dantrolene sodium. The patient was returned to the ward three days later. As the patient showed no other complication, he was discharged.
CONCLUSIONS
In malignant hyperthermia, early diagnosis, appropriate management, and prompt administration of dantrolene sodium are important factors for better prognosis. Preoperatively, full explanation of possible complication and history taking are needed. Careful observation is necessary during anesthesia and surgery.

Keyword

Malignant hyperthermia; Partially accommodative esotropia

MeSH Terms

Anesthesia
Anesthesia, General
Child
Dantrolene
Early Diagnosis
Esotropia
Fever
Humans
Hyperopia
Inhalation
Intensive Care Units
Malignant Hyperthermia
Methyl Ethers
Muscle, Skeletal
Ophthalmology
Prognosis
Risk Factors
Strabismus
Tachycardia
Dantrolene
Methyl Ethers

Reference

References

1. Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anesth Soc J. 1970; 17:293–315.

2. Demeyere R. Malignant hyperthermia. Acta Anaesthesiol Belg. 1978; 29:101–20.

3. Britt BA, Endrenyi L, Peters PL. . Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations. Can Anaesth Soc J. 1976; 23:263–84.

4. Tammisto T, Brander P, Airaksinen MM. . Strabismus as a possible sign of latent muscular disease predisposing to suxamethonium induced muscular injury. Farmatsiia. 1970; 19:126–30.

5. Larach MG, Localio AR, Allen GC. . A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994; 80:771–9.

6. Britt BA, Locher WG, Kalow W. Hereditary aspects of malignant hyperthermia. Can Anaesth Soc J. 1969; 16:89–98.

7. Isaacs H, Barlow MB. The genetic background to malignant hyperthyrexia revealed by serum creatine phosphokinase estimations in asymptomatic relatives. Br J Anaesth. 1970; 42:1077–84.

8. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant- hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997; 60:1316–25.

9. Moslehi R, Langlois S, Yam I, Friedman JM. Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree. Am J Med Genet. 1998; 76:21–7.

10. Stewart SL, Hogan K, Rosenberg H, Fletcher JE. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet. 2001; 59:178–84.

11. Iles DE, Lehmann-Horn F, Scherer SW. . Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet. 1994; 3:969–75.

12. Mickelson JR, Gallant EM, Litterer LA. . Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem. 1988; 263:9310–5.

13. Nelson TE, Lin M, Zapata-Sudo G, Sudo RT. Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Clinical implications. Anesthesiology. 1996; 84:1368–79.

14. Yang HS, Park SH, Kim DY, Suh BT. Analysis of reported cases of malignant hyperthermia in Korea. Korean J Anesthesiol. 1999; 37:105–12.

15. Lee HS, Hong KY, Chung YT. Serologic evaluations and the effect of dantrium(R) for preventing malignant hyperthermia in strabismus children. J Korean Ophthalmol Soc. 1987; 28:787–92.